Chief Judge Mitchell Goldberg tripled to $285 million the damages he had ordered CVS Caremark to pay in June, citing the ...

Whistleblower Sarah Behnke's lawsuit leads to a $290 million judgment against CVS Caremark for overcharging Medicare on ...

CVS Health, which operates the largest U.S. pharmacy benefit manager, will not add Gilead Sciences’ new HIV prevention drug ...

A federal judge has ordered CVS Caremark to pay nearly $290 million in damages after determining the pharmacy benefit manager overbilled Medicare for prescription drugs, according to court documents ...

A federal judge has ordered CVS Caremark to pay almost $290 million in damages and penalties after a whistleblower proved the ...

A federal judge has ordered CVS Health's PBM Caremark to pay nearly $290 million after a whistleblower accused the business of overcharging Medicare on prescription drugs more than a decade ago.

A Pennsylvania judge has ordered CVS to pay $289 million in damages as part of a long-running whistleblower case. | A ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

CVS Health hiked its 2025 forecast above Wall Street’s expectations after improving Medicare benefits contributed to a better-than-expected first quarter. The health care giant said Thursday ...

UBS upgraded CVS Health (NYSE:CVS) to Buy from Neutral and raised its price target to $79, saying recent cost controls and execution in the company’s healthcare benefits arm are beginning to show ...

Overall, CVS Health booked adjusted earnings of $2.25 per share as the company’s profit soared 60% to $1.78 billion in the year’s first quarter. Total revenue climbed 7% to $94.59 billion.